Latest Asx News

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Neometals Ltd has reported impressive new copper assay results from its historic Rinaldi workings within the Barrambie Gold Project, setting the stage for imminent drilling to explore this high-grade opportunity further.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Caterpillar has finalized its acquisition of RPMGlobal, paying shareholders A$5.00 per share and prompting RPMGlobal’s removal from the ASX. This marks a significant shift in the mining software landscape.

Judo Capital Holdings Limited has announced a quarterly distribution of AUD 1.825 per capital note, fully franked and payable on 18 May 2026. The payment reflects a calculated yield based on prevailing market rates and remains subject to company discretion.

BKI Investment Company has finalised its on-market share purchases to satisfy its Dividend Reinvestment Plan obligations, setting the DRP price at $1.74 ahead of the 2026 interim dividend payment.

IDT Australia reports a robust 20.3% increase in core revenue and a dramatic narrowing of EBITDA losses, signalling early success from its strategic realignment under new leadership.

Atturra Limited confirms its FY26 revenue and EBITDA guidance, acknowledging a contract termination impact in H1 but optimistic about a stronger second half.

PhosCo Ltd has raised $5 million through a strongly supported share placement to fund exploration and development at its Gasaat Phosphate Project in Tunisia, positioning the company for upcoming resource milestones.